Protein Degradation Targeting Chimera (PROTAC) Market
Protein Degradation Targeting Chimera (PROTAC)
Market Scope: Industry Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Protein Degradation Targeting Chimera (PROTAC)
Market Size and Growth
The Protein Degradation Targeting Chimera (PROTAC) market is experiencing significant growth, driven by advancements in targeted therapies and increased investment in drug development. The global market size was valued at approximately $1.2 billion in 2023. Projections indicate sustained expansion as research progresses into novel applications and technologies within this innovative therapeutic area.
Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Arvinas
◍ Pfizer
◍ Kymera
◍ Nurix
◍ C4 Therapeutics
◍ Inc.
◍ Astellas Pharma Inc.
◍ AbbVie
◍ Captor therapeutics
◍ Amgen
◍ Oerth Bio
◍ Bayer
◍ Kaituo Pharmaceutical
◍ Haichuang Pharmaceutical
◍ Betta Pharmaceuticals
◍ BeiGene
◍ East China Pharmaceutical Group
The PROTAC market features key players like Arvinas, Pfizer, and Kymera, focusing on innovative therapies that enhance targeted protein degradation. Companies like Astellas and AbbVie drive growth through strategic partnerships and R&D investments. Sales revenue highlights include Arvinas' $100M and Pfizer's $50M in 2023, fueling industry expansion.
◍ Hengrui Medicine
Request Sample Report
Market Segmentation
By Application
By Product
Based on VHL ◍ Breast Cancer
◍ Based on CRBN
◍ Prostate Cancer
◍ Colorectal Cancer
◍ Pancreatic Cancer ◍ Lymphoma ◍ Androgenic Alopecia ◍ Others
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
